Barbara Iyen1, Nadeem Qureshi2, Stephen Weng2, Paul Roderick3, Joe Kai2, Nigel Capps4, Paul N Durrington5, Ian Fw McDowell6, Handrean Soran7, Andrew Neil8, Steve E Humphries9. 1. Primary Care Stratified Medicine Group, Division of Primary Care, University of Nottingham, UK. Electronic address: barbara.iyen@nottingham.ac.uk. 2. Primary Care Stratified Medicine Group, Division of Primary Care, University of Nottingham, UK. 3. Faculty of Medicine, Primary Care and Population Sciences, University of Southampton, UK. 4. Department of Clinical Biochemistry, The Shrewsbury and Telford Hospital NHS Trust, Princess Royal Hospital, Telford, UK. 5. Cardiovascular Research Group, School of Clinical and Laboratory Sciences, University of Manchester, UK. 6. Department of Medical Biochemistry and Immunology, University Hospital of Wales, Cardiff, UK. 7. Centre for Diabetes, Endocrinology and Metabolism, Manchester University Hospitals NHS Foundation Trust, Manchester, UK. 8. Wolfson College, University of Oxford, UK. 9. Centre for Cardiovascular Genetics, Institute of Cardiovascular Science, University College London, University Street, London, UK.
Abstract
BACKGROUND AND AIMS: The UK Simon Broome (SB) familial hypercholesterolaemia (FH) register previously reported 3-fold higher standardised mortality ratio for cardiovascular disease (CVD) in women compared to men from 2009 to 2015. Here we examined sex differences in CVD morbidity in FH by national linkage of the SB register with Hospital Episode Statistics (HES). METHODS: Of 3553 FH individuals in the SB register (aged 20-79 years at registration), 2988 (52.5% women) had linked HES records. Standardised Morbidity Ratios (SMbR) compared to an age and sex-matched UK general practice population were calculated [95% confidence intervals] for first CVD hospitalisation in HES (a composite of coronary heart disease (CHD), myocardial infarction (MI), stable or unstable angina, stroke, TIA, peripheral vascular disease (PVD), heart failure, coronary revascularisation interventions). RESULTS: At registration, men had significantly (p < 0.001) higher prevalence of previous CHD (24.8% vs 17.6%), previous MI (13.2% vs 6.3%), and were commenced on lipid-lowering treatment at a younger age than women (37.5 years vs 42.3 years). The SMbR for composite CVD was 6.83 (6.33-7.37) in men and 7.55 (6.99-8.15) in women. In individuals aged 30-50 years, SMbR in women was 50% higher than in men (15.04 [12.98-17.42] vs 10.03 [9.01-11.17]). In individuals >50 years, SMbR was 33% higher in women than men (6.11 [5.57-6.70] vs 4.59 [4.08-5.15]). CONCLUSIONS: Excess CVD morbidity due to FH remains markedly elevated in women at all ages, but especially those aged 30-50 years. This highlights the need for earlier diagnosis and optimisation of lipid-lowering risk factor management for all FH patients, with particular attention to young women with FH.
BACKGROUND AND AIMS: The UK Simon Broome (SB) familial hypercholesterolaemia (FH) register previously reported 3-fold higher standardised mortality ratio for cardiovascular disease (CVD) in women compared to men from 2009 to 2015. Here we examined sex differences in CVD morbidity in FH by national linkage of the SB register with Hospital Episode Statistics (HES). METHODS: Of 3553 FH individuals in the SB register (aged 20-79 years at registration), 2988 (52.5% women) had linked HES records. Standardised Morbidity Ratios (SMbR) compared to an age and sex-matched UK general practice population were calculated [95% confidence intervals] for first CVD hospitalisation in HES (a composite of coronary heart disease (CHD), myocardial infarction (MI), stable or unstable angina, stroke, TIA, peripheral vascular disease (PVD), heart failure, coronary revascularisation interventions). RESULTS: At registration, men had significantly (p < 0.001) higher prevalence of previous CHD (24.8% vs 17.6%), previous MI (13.2% vs 6.3%), and were commenced on lipid-lowering treatment at a younger age than women (37.5 years vs 42.3 years). The SMbR for composite CVD was 6.83 (6.33-7.37) in men and 7.55 (6.99-8.15) in women. In individuals aged 30-50 years, SMbR in women was 50% higher than in men (15.04 [12.98-17.42] vs 10.03 [9.01-11.17]). In individuals >50 years, SMbR was 33% higher in women than men (6.11 [5.57-6.70] vs 4.59 [4.08-5.15]). CONCLUSIONS: Excess CVD morbidity due to FH remains markedly elevated in women at all ages, but especially those aged 30-50 years. This highlights the need for earlier diagnosis and optimisation of lipid-lowering risk factor management for all FHpatients, with particular attention to young women with FH.
Authors: Amanda M Perak; Hongyan Ning; Sarah D de Ferranti; Holly C Gooding; John T Wilkins; Donald M Lloyd-Jones Journal: Circulation Date: 2016-07-05 Impact factor: 29.690
Authors: H A W Neil; M M Hawkins; P N Durrington; D J Betteridge; N E Capps; S E Humphries Journal: Atherosclerosis Date: 2004-12-08 Impact factor: 5.162
Authors: Kirsten B Holven; Ingunn Narverud; Jeanine Roeters van Lennep; Jorie Versmissen; Linn K L Øyri; Annette Galema-Boers; Gisle Langslet; Stine M Ulven; Marit B Veierød; Kjetil Retterstøl; Martin P Bogsrud Journal: J Clin Lipidol Date: 2018-03-09 Impact factor: 4.766
Authors: Nadeem Qureshi; Ralph Kwame Akyea; Stephen F Weng; Joe Kai; Brittany Dutton; Steve E Humphries; Hasidah Abdul Hamid; Laura Condon Journal: Heart Date: 2021-09-14 Impact factor: 5.994
Authors: Matthew Jones; Ralph K Akyea; Katherine Payne; Steve E Humphries; Hasidah Abdul-Hamid; Stephen Weng; Nadeem Qureshi Journal: J Pers Med Date: 2022-02-22